Brought to you by 
Merck and Eisai co-develop Lenvima; expand combination trials
22 Oct 2021
Executive Summary
Merck & Co. Inc. and Eisai Co. Ltd. will co-develop and co-commercialize Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) both as a monotherapy and in combination with Merck’s Keytruda (pembrolizumab).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com